ALS Therapy Development Institute
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ALS Therapy Development Institute
Investigators have completed the algorithm development and clinical validation studies of objective, electroencephalogram-based technology in adolescent and young adult populations, the company says. The studies were funded by a $9.9m research contract from the US Department of Defense, award funding from the National Football League-GE Head Health Challenge, and BrainScope.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.
BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injury. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.